The Result: Arthritis drug found effective in treating sickest COVID-19 intensive care patients.
November 2020.
Read more ยป
REMAP-CAP is a Randomized, Embedded, Multifactorial Adaptive Platform trial for Community-Acquired Pneumonia. The primary aim of the study is to identify the effect of a range of interventions to improve all-cause mortality at 90 days.
Spinnaker is a tailored, web based, software and database solution for managing your multi-centre clinical study including the recording of patient data, recording and alerting of events, inventory management and reporting on data collected during the course of your study. Spinnaker is user friendly, adaptable and can be delivered quickly. You can read more on the Spinnaker website or contact Audrey on spinnaker@spiral.co.nz.
You can get to know us a little better through our blog and social media pages accessed via the logout screen of this trial.
This instance of REMAP-CAP hosted on our MAGPIE server